List of Excipients in Branded Drug ASCORBIC ACID

✉ Email this page to a colleague

Generic Drugs Containing ASCORBIC ACID

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	ascorbic acid	65219-027	EDETATE DISODIUM
Fresenius Kabi USA LLC	ascorbic acid	65219-027	SODIUM BICARBONATE
Fresenius Kabi USA LLC	ascorbic acid	65219-027	SODIUM HYDROXIDE
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in ASCORBIC ACID?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
2	EDETATE DISODIUM
2	SODIUM BICARBONATE
2	SODIUM HYDROXIDE
># Of NDCs	>Excipient

Ascorbic Acid Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: September 2, 2026

Ascorbic acid is a high-volume, low-cost pharmaceutical active ingredient and excipient with established antioxidant, pH-adjusting, chelating, and stability-enhancing functions. Its strongest commercial opportunities are in oxygen-sensitive formulations, oral solid-dose products, effervescent systems, liquid products, parenteral formulations, and combination products that require oxidation control.

The core commercial constraint is commoditization. Basic ascorbic acid is available from multiple global suppliers, while meaningful differentiation usually requires formulation know-how, controlled particle engineering, low-impurity grades, co-processed excipient systems, packaging technology, or a drug-specific stability package.

What excipient functions does ascorbic acid provide?

Ascorbic acid, also known as vitamin C or L-ascorbic acid, has several pharmaceutical excipient functions:

Function	Formulation role	Commercial value
Antioxidant	Scavenges oxygen-derived radicals and reduces oxidation of sensitive ingredients	High in liquid and oxygen-sensitive products
Reducing agent	Maintains selected ingredients in a reduced state	Relevant to biologics, vitamins, and oxidation-sensitive APIs
Chelating support	Can interact with trace metals, although dedicated chelators may be more effective	Useful as part of a broader stabilization system
pH modifier	Acidifies formulations and contributes to buffer systems	Important in oral liquids, effervescent products, and topical preparations
Active ingredient	Supplies vitamin C for prevention or treatment of deficiency	Large established market, limited differentiation
Taste and sensory modifier	Provides sourness in oral products	Useful in chewables, powders, and beverages
Effervescent acid	Reacts with bicarbonates or carbonates to generate carbon dioxide	Enables fast-dissolving oral dosage forms
Nutrient stabilizer	Supports nutritional and multivitamin formulations	Relevant to combination products and parenteral nutrition

Ascorbic acid does not function as a universal antioxidant. Its performance depends on pH, oxygen exposure, light, metal contamination, water activity, concentration, container closure, and interactions with the API. In some systems, ascorbic acid can promote degradation through redox cycling, particularly in the presence of transition metals. Formulation screening is therefore required before commercial adoption.

Which pharmaceutical dosage forms use ascorbic acid?

Oral solid dosage forms

Ascorbic acid is widely used in:

Immediate-release tablets
Chewable tablets
Capsules
Powder sachets
Granules
Effervescent tablets
Orally disintegrating and rapidly dissolving formats
Multivitamin and mineral combinations

In tablets, the main technical issues are hygroscopicity, acid-base reactivity, compression behavior, taste, and stability. Direct compression can be difficult when the selected ascorbic acid grade has poor flow or when the formulation contains moisture-sensitive excipients.

Granulation may improve flow and content uniformity but can accelerate degradation if water or heat is introduced. Dry granulation, roller compaction, or specialized direct-compression grades may offer a better stability profile.

Oral liquids and syrups

Ascorbic acid is used as an active ingredient, antioxidant, pH modifier, or both. Oral liquids create a more demanding stability environment because dissolved ascorbic acid is more vulnerable to oxygen, light, elevated temperature, and catalytic metals.

Commercially relevant controls include:

Low-oxygen manufacturing and filling
Nitrogen headspace management
Chelator use where justified
Light-protective containers
Low-permeability closures
Appropriate pH control
Preservative compatibility
Reduced metal contamination
Validated assay and degradation-product methods

Liquid products provide greater opportunity for formulation differentiation than ordinary tablets because packaging and process design materially affect shelf life.

Effervescent dosage forms

Effervescent products combine an acid source with a carbonate or bicarbonate. Ascorbic acid can be both the therapeutic ingredient and the acid component.

Key development risks include:

Premature reaction caused by moisture
Carbon dioxide loss
Caking
Reduced dissolution performance
Assay drift
Packaging failure
Incompatibility with alkaline minerals or APIs

Aluminum-aluminum blister packaging, high-barrier tubes, desiccants, and low-moisture processing are often central to the product design. The commercial opportunity is strongest where rapid dissolution, high dose delivery, and consumer convenience justify a premium over conventional tablets.

Parenteral formulations

Ascorbic acid injection products use the ingredient as an active therapeutic component. Ascorbic acid may also be investigated as an antioxidant or reducing agent in injectable systems, but parenteral use imposes strict requirements for sterility, endotoxin control, particulate matter, pH, osmolality, container compatibility, and degradation control.

The injectable market has higher technical barriers than oral products. Opportunities exist in:

Sterile, ready-to-use presentations
Concentrated and diluted infusion formats
Improved light protection
Lower impurity profiles
Compatible co-packaged diluents
Hospital-ready packaging
Stability-enhanced formulations

FDA approval of an injectable product depends on the complete drug product and manufacturing process. Pharmaceutical-grade bulk material alone does not establish suitability for injection.

Topical and dermatological products

Ascorbic acid is used in topical products for cosmetic and dermatological purposes. The molecule is unstable in aqueous formulations and can oxidize, producing discoloration and reduced potency.

Commercial approaches include:

Anhydrous systems
Water-free powders
Two-compartment packaging
Fresh-mix delivery
Encapsulation
Lipid or polymer carriers
Derivative forms such as sodium ascorbyl phosphate or magnesium ascorbyl phosphate

These products often compete in the cosmetic rather than prescription-drug market. A topical product containing ascorbic acid may require a different regulatory strategy depending on its claims, concentration, route, and jurisdiction.

How should manufacturers select an ascorbic acid excipient grade?

Grade selection should be based on function and risk rather than price alone.

Grade attribute	Why it matters
Particle size distribution	Controls flow, blend uniformity, dissolution, and compression
Bulk and tapped density	Affects tablet weight and equipment throughput
Moisture content	Drives hydrolysis, caking, effervescence, and stability risk
Residual solvents and elemental impurities	Relevant to ICH Q3C and Q3D compliance
Microbial quality	Critical for oral liquids and sterile products
Color and clarity	Important for liquids, injectables, and premium products
Assay and impurity profile	Determines consistency and degradation margin
Surface area	Influences dissolution and oxidation
Crystal form	Can affect processing and stability
Packaging configuration	Controls moisture and oxygen ingress
Supply-chain continuity	Reduces risk from a concentrated manufacturing base

For ordinary tablets, a standard pharmaceutical grade may be adequate. For high-dose tablets, effervescent products, and direct compression, engineered particle size and flow performance can create measurable value. For liquids and injectables, low-metal, low-bioburden, high-purity material and packaging compatibility are more important than compression behavior.

The supplier should provide a complete certificate of analysis, change-control commitments, elemental impurity information, residual solvent data, microbial specifications, and applicable compendial compliance.

What formulation strategies improve ascorbic acid stability?

Control oxygen and metal exposure

Ascorbic acid degradation is strongly influenced by oxygen and trace metals. A practical stabilization program can include:

Raw-material control for copper, iron, and other catalytic metals.
Purified water with controlled metal content.
Deaeration or nitrogen sparging.
Low-oxygen filling.
Chelator screening where compatible.
Light-protective packaging.
Validated closure-integrity testing.

The chelator should be selected based on the product and regulatory status. Disodium edetate is commonly evaluated in pharmaceutical stabilization programs, but it can alter the behavior of other ingredients and must be justified through formulation data.

Optimize pH

Ascorbic acid stability is pH-dependent. The target pH must balance chemical stability, palatability, preservative efficacy, API solubility, tissue tolerability, and container compatibility.

In aqueous products, a lower pH can improve stability in certain systems, but it can also increase irritation, affect excipient performance, or destabilize another active ingredient. A pH target should therefore be established through forced-degradation and real-time stability work, not selected from generic vitamin C formulations.

Use dry or protected delivery systems

For oxidation-sensitive or high-value products, commercial options include:

Dry powder for reconstitution
Dual-chamber containers
Encapsulated ascorbic acid
Lipid-based carriers
Polymer-coated particles
Spray-dried systems
Anhydrous concentrates
Single-dose packaging

These approaches can increase manufacturing and packaging costs, but they may support premium pricing and stronger formulation protection.

Separate incompatible ingredients

Ascorbic acid can react with alkaline ingredients, oxidizing agents, some minerals, and certain APIs. Physical separation may be preferable to attempting to stabilize the full combination in one phase.

Examples include:

Bilayer tablets
Multiparticulates
Separate sachet compartments
Dual-chamber liquid systems
Coated granules
Sequential reconstitution

Separation can improve shelf life and reduce the need for high antioxidant concentrations.

What patents can protect an ascorbic acid formulation?

Basic ascorbic acid composition claims are generally weak because the molecule and many conventional uses are long established. Commercially relevant protection is more likely to arise from narrow formulation, process, delivery, or combination claims.

Formulation patents

Potential claim categories include:

Defined ascorbic acid concentration ranges
Specific pH and buffer systems
Low-metal compositions
Defined antioxidant and chelator combinations
Encapsulated ascorbic acid particles
Moisture-controlled effervescent compositions
Anhydrous topical systems
Specific particle-size distributions
Controlled-release dosage forms
Improved dissolution or bioavailability systems
Sterile injectable compositions
Container-closure combinations
Reconstitutable products with improved stability

A patent claim needs a credible technical effect. Stability data should demonstrate a measurable advantage against an appropriate comparator, such as longer assay retention, lower discoloration, reduced degradation products, or improved dissolution after storage.

Method-of-use patents

Method-of-use protection may be available for a particular therapeutic use if the use is novel and patentable in the relevant jurisdiction. The opportunity is limited for conventional vitamin C supplementation because many nutritional and therapeutic uses are well established.

More defensible use claims may involve:

A specific patient population
A defined dosing schedule
A biomarker-selected group
A combination with another therapy
A route-specific regimen
A disease setting with demonstrated clinical benefit

Use claims require clinical support. Formulation novelty alone does not create a new therapeutic indication.

Manufacturing and process patents

Process claims can target:

Low-oxygen manufacturing
Particle engineering
Agglomeration
Spray drying
Encapsulation
Sterile compounding
Degradation-product reduction
Continuous manufacturing
Improved crystallization
Reduced impurity formation

Process patents may be commercially useful when the process is difficult to design around or materially reduces cost. Their value is lower when competitors can obtain equivalent material through conventional processes.

Packaging patents

Packaging can be a meaningful source of protection for ascorbic acid products. Claims may cover:

High-barrier containers
Nitrogen-filled headspace
Desiccant-integrated packaging
Multi-compartment delivery systems
Oxygen scavengers
Light-protective container structures
Unit-dose reconstitution devices

Packaging claims should be integrated with stability data and product-specific performance. A generic claim to a light-resistant container is unlikely to create strong exclusivity by itself.

What is the FDA regulatory status of ascorbic acid as an excipient?

Ascorbic acid has broad compendial and pharmaceutical use, but its regulatory treatment depends on how it is used.

For a finished drug product, the sponsor must establish that each inactive ingredient is suitable for the route, dose, concentration, and dosage form. FDA’s Inactive Ingredient Database is commonly used to assess prior precedent, but database presence does not automatically establish approval for a new route or concentration.[1]

Relevant regulatory considerations include:

USP or applicable pharmacopeial compliance
FDA inactive-ingredient precedent
Drug Master File strategy
ICH Q3A and Q3B impurity assessment where applicable
ICH Q3C residual solvent control
ICH Q3D elemental impurity control
Microbial limits
Nitrosamine risk assessment where relevant
Extractables and leachables
Container-closure integrity
Stability-indicating analytical methods
GMP qualification and supplier change control

For an ascorbic acid product marketed as a drug, the active ingredient must meet the applicable quality and regulatory requirements for the finished product. For a formulation marketed as a dietary supplement or cosmetic, the regulatory pathway and allowable claims differ materially.

What Orange Book and Paragraph IV issues apply to ascorbic acid products?

A conventional ascorbic acid tablet or capsule is unlikely to have a commercially meaningful patent barrier based solely on the molecule. Orange Book relevance depends on the specific approved drug product and whether the sponsor has listed eligible patents covering the product, formulation, method of use, or device.

For a generic applicant, relevant issues include:

Whether the reference product has listed patents
Whether any listed patent covers the proposed formulation or method
Whether a Paragraph IV certification is required
Whether the product has unexpired regulatory exclusivity
Whether the applicant can design around formulation claims
Whether the reference product has a therapeutically equivalent listing
Whether labeling and route of administration match the reference product

A Paragraph IV challenge is commercially meaningful only when an approved reference product has listed, enforceable patents with remaining term. For ordinary vitamin C products, the larger barriers are often regulatory equivalence, manufacturing quality, stability, market access, and price competition rather than patent litigation.

Patent-term calculations must be performed from the actual patent records, including patent-term adjustment, patent-term extension, terminal disclaimers, disclaimers, and jurisdiction-specific rules. No universal expiration date applies to all ascorbic acid products.

How strong is the patent estate for ascorbic acid?

The overall patent estate is weak for commodity ascorbic acid and stronger for specialized delivery systems.

Product strategy	Expected patent strength	Primary protection
Conventional vitamin C tablet	Low	Brand, manufacturing scale, quality, distribution
Chewable or flavored tablet	Low to moderate	Composition and taste-masking claims
Effervescent tablet	Moderate	Moisture-control, granulation, packaging, dissolution
Stabilized oral liquid	Moderate	pH, chelator, oxygen control, packaging
Injectable ascorbic acid	Moderate	Composition, concentration, sterility, packaging, use
Encapsulated ascorbic acid	Moderate to strong	Particle structure, carrier, release, process
Topical anhydrous vitamin C	Moderate	Water-free composition, delivery system, packaging
Combination product with novel API	Moderate to strong	Combination, dosing, method of use
Specialized reconstitution device	Moderate	Device and formulation combination

The strongest portfolio strategy is usually layered:

Composition patent for the formulation.
Process patent for manufacturing.
Packaging or device patent.
Method-of-use patent where clinically justified.
Trade-secret protection for process parameters and supplier controls.

Patent owners should avoid relying on a single narrow concentration or pH claim. Competitors can often design around such claims through small changes in excipient ratios, packaging, or process conditions.

Which companies compete in the ascorbic acid supply chain?

The supply chain includes bulk API manufacturers, pharmaceutical excipient distributors, contract manufacturers, supplement producers, and finished-dose pharmaceutical companies. Global production has historically been concentrated among Asian manufacturers, particularly in China, while European and U.S. companies participate through specialty ingredients, distribution, formulation, and finished products.

The competitive landscape should be evaluated across:

GMP certification
Drug Master File availability
Compendial status
Batch-size capability
Particle engineering
Low-metal grades
Sterile manufacturing capability
Regulatory inspection history
Supply continuity
Lead time
Packaging performance
Regional inventory

Supplier concentration can create commercial leverage for qualified producers with validated alternate sources. A formulation company that qualifies two independent suppliers may reduce interruption risk but must control equivalence, change management, and stability impact.

What commercial opportunities exist for ascorbic acid excipients?

Premium pharmaceutical grades

The strongest near-term opportunity is not standard ascorbic acid. It is value-added material with:

Controlled particle size
Improved flow
Low moisture
Low elemental impurities
Reduced bioburden
Better compressibility
Defined surface treatment
Consistent dissolution

A premium grade can command higher pricing if it reduces tablet defects, improves throughput, or shortens formulation development.

Effervescent and fast-dissolving products

Effervescent vitamin C products remain commercially attractive because they support higher perceived convenience and sensory differentiation. The product economics depend on packaging, flavor systems, mineral combinations, and retail positioning.

The principal IP opportunity is an integrated formulation and package that maintains performance under humidity stress.

Stabilized liquid products

Liquid stability remains a technical challenge. A system that extends shelf life without refrigeration, reduces discoloration, or permits a lower preservative burden can support licensing or contract-development revenue.

Injectable and hospital products

Sterile ascorbic acid products may support higher margins than oral supplements, particularly where the product is supplied in ready-to-use formats or institutional packaging. The barriers are higher because the sponsor must demonstrate sterile manufacturing control and product quality.

Topical delivery systems

Water-free, encapsulated, or fresh-mix topical products can command premium pricing. The addressable market is split between cosmetics, dermatology, and potential pharmaceutical products, each with different claim and evidence requirements.

Combination products

Ascorbic acid can be included in multivitamin, mineral, nutritional, and therapeutic combinations. A defensible opportunity exists where the combination solves a stability or adherence problem rather than simply aggregating known ingredients.

Contract development and manufacturing

CDMOs can monetize:

Stability screening
Excipient compatibility studies
Dry blending and granulation
Effervescent manufacturing
Liquid filling
Sterile filling
Encapsulation
Reconstitution packaging
Analytical method development
Accelerated and long-term stability programs

The best margin profile is likely in integrated development and manufacturing rather than bulk ingredient resale.

How does ascorbic acid compare with other pharmaceutical antioxidants?

Antioxidant	Relative advantages	Main limitations
Ascorbic acid	Familiar, low cost, water soluble, active ingredient potential	Oxidation-sensitive, pH-dependent, can interact with metals
Sodium metabisulfite	Effective in selected aqueous systems, low cost	Sulfite sensitivity, odor, route limitations
Sodium bisulfite	Useful reducing agent	Sulfite-related safety and compatibility issues
Tocopherol	Lipid soluble, useful in oils and emulsions	Poor water solubility, oxidation and dispersion issues
Butylated hydroxytoluene	Effective lipid-phase antioxidant	Regulatory and formulation acceptance constraints
Butylated hydroxyanisole	Lipid-phase protection	Taste, regulatory, and consumer-perception concerns
Edetate salts	Metal chelation	Not a complete antioxidant and requires compatibility review

Ascorbic acid is strongest when the formulation needs both a reducing agent and a vitamin C active. It is less attractive where long-term aqueous stability is required without tight oxygen and metal control.

What generic entry risks exist for ascorbic acid products?

Generic entry risk is high for simple oral products and lower for complex formulations.

High generic-entry-risk products

Conventional immediate-release tablets
Standard capsules
Simple powders
Basic oral solutions with established excipient systems
Products with no meaningful listed patents
Products with widely available raw materials

Moderate generic-entry-risk products

Effervescent tablets
Flavored chewables
Stabilized oral liquids
Modified-release products
Combination products with formulation-specific claims

Lower generic-entry-risk products

Sterile injectable systems
Encapsulated delivery systems
Proprietary reconstitution devices
Complex multi-phase formulations
Products with clinically supported method-of-use claims
Products with difficult-to-reproduce particle engineering

Regulatory complexity, manufacturing validation, and stability data often provide more practical protection than patents. This protection is vulnerable to competitors with established sterile or specialized manufacturing capacity.

What licensing opportunities are available?

Potential licensing models include:

Opportunity	Licensor asset	Likely licensee
Low-moisture effervescent platform	Formulation and packaging IP	OTC and supplement manufacturer
Stabilized oral liquid	Composition, process, and stability data	Pediatric or consumer-health company
Injectable formulation	Sterile formulation and manufacturing package	Hospital pharmaceutical company
Encapsulated vitamin C	Delivery technology	Specialty nutrition or dermatology company
Premium direct-compression grade	Excipient engineering and supply	Tablet manufacturer
Dual-chamber reconstitution system	Device and product combination	Pharmaceutical packaging company
Low-impurity supply platform	Qualified manufacturing process	Generic or contract manufacturer

A licensable package should include composition claims, process parameters, analytical methods, stability data, scale-up results, and regulatory documentation. A patent alone is less valuable when the formulation cannot be transferred reliably at commercial scale.

What geographic coverage should an ascorbic acid strategy target?

The commercial and IP strategy should separate high-value regulatory markets from manufacturing jurisdictions.

United States

Key issues include FDA approval, Orange Book listings, inactive-ingredient precedent, patent listing eligibility, ANDA strategy, and Paragraph IV exposure.

European Union

The strategy should address centralized or national approval, European Pharmacopoeia compliance, supplementary protection certificate rules where relevant, and national patent litigation.

China and India

These jurisdictions are important for manufacturing, sourcing, generic competition, and process protection. Supplier qualification and freedom-to-operate review are critical because process and formulation rights may differ by country.

Japan and South Korea

These markets can support premium pharmaceutical and consumer-health products but require local regulatory and distribution strategies.

Emerging markets

Latin America, Southeast Asia, and the Middle East may offer volume opportunities for stable, low-cost oral products. Packaging performance becomes especially important in hot and humid climates.

Patent filing should prioritize markets where the product will be manufactured, sold, licensed, or challenged. Broad global filing is difficult to justify for a low-value commodity formulation unless the technology has strong platform potential.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are:

Consistent pharmaceutical-grade supply
Control of oxidation and trace metals
Moisture management
Scale-up of particle engineering
Compression and blend uniformity
Effervescent packaging
Sterile manufacturing for injections
Validated stability-indicating methods
Regulatory qualification of suppliers
Product-specific intellectual property
Regional freedom-to-operate
Reliable commercial packaging

For a standard oral tablet, manufacturing barriers are low. For a sterile, encapsulated, or humidity-sensitive product, barriers increase sharply. A company seeking durable commercial advantage should invest in process capability, analytical control, and packaging integration rather than relying only on ascorbic acid composition claims.

What is the commercial outlook for ascorbic acid excipient innovation?

The bulk market will remain price competitive. Growth is more likely in specialized applications where ascorbic acid solves a defined formulation problem:

Oxidation-sensitive active ingredients
Stable liquid and pediatric products
Effervescent and rapid-delivery products
Sterile hospital formulations
Encapsulated and anhydrous topical systems
Premium direct-compression grades
High-barrier and reconstitution packaging
Combination products with improved shelf life

The most attractive strategy is a platform based on stability, delivery, and manufacturing performance. A company that sells only commodity ascorbic acid will face low margins and limited patent leverage. A company that supplies a qualified grade together with formulation design, packaging, regulatory support, and manufacturing transfer can capture substantially more value.

Key Takeaways

Ascorbic acid is a mature, low-cost ingredient with broad pharmaceutical utility.
Its principal excipient roles are antioxidant, reducing agent, pH modifier, chelation support, and effervescent acid.
Conventional tablets have high generic risk and weak composition-patent potential.
Liquid, injectable, effervescent, topical, encapsulated, and reconstitutable products offer stronger differentiation.
Stability depends on oxygen, light, pH, moisture, trace metals, packaging, and process conditions.
Premium excipient grades can be differentiated through particle size, flow, moisture, impurity, and microbial controls.
Orange Book and Paragraph IV issues are product-specific and generally less important for ordinary vitamin C products than manufacturing and regulatory equivalence.
The strongest IP portfolios combine formulation, process, packaging, and clinically supported method-of-use claims.
Licensing value is highest when the technology includes scale-up data, analytical methods, stability results, and regulatory documentation.
Commercial returns are more attractive in integrated formulation and CDMO services than in bulk ascorbic acid sales.

Frequently Asked Questions

Can ascorbic acid replace sodium metabisulfite as a pharmaceutical antioxidant?

Sometimes. The answer depends on pH, API compatibility, oxygen exposure, route of administration, sulfite sensitivity, and degradation pathways. Comparative forced-degradation and stability studies are required.

Is ascorbic acid suitable for injectable formulations?

Yes, as an approved active ingredient in certain injectable products. Use as an excipient in another injectable requires route-specific safety, sterility, impurity, compatibility, and regulatory justification.

Can a company patent a vitamin C tablet?

A conventional vitamin C tablet is unlikely to support strong patent protection. Patentability improves when the product includes a novel stabilization system, delivery structure, manufacturing process, packaging system, or clinically supported use.

What packaging is most important for ascorbic acid effervescent tablets?

Moisture-barrier packaging is usually critical. High-barrier blisters or tubes, desiccants, controlled humidity during manufacture, and validated closure integrity can materially affect shelf life.

Is encapsulated ascorbic acid commercially defensible?

It can be. The strongest defensibility comes from a reproducible carrier structure, demonstrated stability or bioavailability improvement, manufacturing know-how, and claims that competitors cannot easily design around.

References

U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
International Council for Harmonisation. (2005). Q8(R2): Pharmaceutical development.
International Council for Harmonisation. (2006). Q9: Quality risk management.
International Council for Harmonisation. (2008). Q10: Pharmaceutical quality system.
International Council for Harmonisation. (2009). Q3C(R8): Impurities: Guideline for residual solvents.
International Council for Harmonisation. (2014). Q3D(R2): Guideline for elemental impurities.
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
Davey, M. W., Van Montagu, M., Inzé, D., Sanmartin, M., Kanellis, A., Smirnoff, N., Benzie, I. J. J., Strain, J. J., Favell, D., & Fletcher, J. (2000). Plant L-ascorbic acid: Chemistry, function, metabolism, bioavailability and effects of processing. Journal of the Science of Food and Agriculture, 80(7), 825-860. https://doi.org/10.1002/(SICI)1097-0010(20000515)80:7<825::AID-JSFA598>3.0.CO;2-6

More… ↓

⤷ Start Trial